# Accelerated Aging Mediates the Associations of Unhealthy Lifestyles with Cardiovascular Disease, Cancer, and Mortality: Two Large Prospective Cohort Studies

4

#### 5 Authors:

- 6 Xueqin Li<sup>1#</sup>, Xingqi Cao<sup>1#</sup>, Jingyun Zhang<sup>1#</sup>, Jinjing Fu<sup>1</sup>, Mayila Mohedaner<sup>1</sup>,
- 7 Danzengzhuoga<sup>1</sup>, Xiaoyi Sun<sup>1</sup>, Gan Yang<sup>1</sup>, Zhenqing Yang<sup>1</sup>, Chia-Ling Kuo<sup>2</sup>, Xi Chen<sup>3</sup>,
- 8 <sup>4</sup>, Alan A Cohen<sup>5</sup>, Zuyun Liu<sup>1\*</sup>

### 9 Affiliations:

- <sup>1</sup>Department of Big Data in Health Science School of Public Health and Center for
- Clinical Big Data and Analytics Second Affiliated Hospital, Zhejiang University School
   of Medicine, Hangzhou 310058, Zhejiang, China
- <sup>12</sup><sup>2</sup>Department of Community Medicine and Health Care, Connecticut Convergence
- 14 Institute for Translation in Regenerative Engineering, Institute for Systems Genomics,
- 15 University of Connecticut Health, Farmington, CT 06030, USA
- <sup>3</sup>Department of Health Policy and Management, Yale School of Public Health, New
   Haven, CT 06520, USA
- <sup>4</sup>Department of Economics, Yale University, New Haven, CT 06520, USA
- <sup>5</sup>Department of Family Medicine, Research Centre on Aging, CHUS Research Centre,
- 20 University of Sherbrooke, Sherbrooke, QC, Canada
- 21
- <sup>#</sup>These authors contributed equally to this work.

#### 23 **\*Corresponding author:**

- 24 Zuyun Liu, Professor, Department of Big Data in Health Science School of Public
- 25 Health and Center for Clinical Big Data and Analytics Second Affiliated Hospital,
- 26 Zhejiang University School of Medicine, 866 Yuhangtang Rd, Hangzhou, 310058,
- 27 Zhejiang, China. Telephone: +86-0571-87077127. Email: Zuyun.liu@outlook.com or
- 28 zuyunliu@zju.edu.cn
- 29

#### 30 Abstract

31 With a well-validated aging measure – Phenotypic Age Acceleration (PhenoAgeAccel),

32 this study examined whether and to what extent aging mediates the associations of

unhealthy lifestyles with adverse health outcomes. Data were from 405,944 adults (40-

- 69 years) from UK Biobank (UKB) and 9,972 adults (20-84 years) from US National
- 35 Health and Nutrition Examination Surveys (NHANES). The mediation proportion of
- 36 PhenoAgeAccel in associations of unhealthy lifestyles with incident cardiovascular
- disease, incident cancer, and all-cause mortality were 20.0%, 17.8%, and 26.6% (P
- values <0.001) in UKB, respectively. The mediation proportion of PhenoAgeAccel in associations of lifestyles with cancer mortality, and all-cause mortality were 25.7%, and

associations of lifestyles with cancer mortality, and all-cause mortality were 25.7%, and 35.2% (P values <0.05) in NHANES, respectively. This study demonstrated that

- 41 accelerated aging partially mediated the associations of lifestyles with adverse health
- 42 outcomes in UK and US populations. The findings reveal a novel pathway and the
- 43 potential of geroprotective programs in mitigating health inequality in late-life beyond
- 44 lifestyle interventions.
- 45 Keywords: Lifestyles; Phenotypic aging; Adverse health outcomes; Mediation analysis
- 46

#### 47 Introduction

Unhealthy lifestyle factors, such as lack of exercise <sup>1</sup>, unhealthy diet <sup>2</sup>, and smoking <sup>3</sup>, 48 are independently associated with multiple adverse health outcomes <sup>4-6</sup>, such as 49 cardiovascular disease (CVD) and all-cause mortality. Furthermore, such factors are 50 associated with each other and tend to have synergistic effects on health <sup>7,8</sup>. A few 51 52 randomized controlled trials have shown that multi-domain and intensive lifestyle interventions as a whole could improve cognitive function and reduce the prevalence 53 of frailty, a geriatric syndrome 9-11. Despite the observed benefit of lifestyle 54 interventions, the potential mechanisms explaining how healthy lifestyles contribute to 55 the reduction of adverse health outcomes remain poorly understood. 56

Accelerated aging is the primary risk factor for chronic diseases and death <sup>12</sup>. 57 Geroscience researchers hypothesize that therapies or preventive programs targeting 58 aging would alleviate the incidence or severity of most chronic diseases <sup>12</sup>. Interestingly, 59 emerging evidence suggests that unhealthy lifestyles are associated with the 60 acceleration of aging in various populations <sup>11,13-18</sup>. For instance, smoking and higher 61 BMI are found to be strongly associated with biological aging <sup>18</sup>. Thus, we hypothesize 62 that aging could play a mediating role in the associations of unhealthy lifestyles with 63 adverse health outcomes, which, however, has rarely been investigated in previous 64 literature. 65

Based on multi-system blood biomarkers, we have previously developed a novel 66 aging measure, Phenotypic Age Acceleration (PhenoAgeAccel)<sup>19-22</sup>. We have 67 demonstrated that this comprehensive aging measure could predict mortality and 68 morbidity across different subpopulations, even among those who are disease-free <sup>22</sup>. 69 70 This aging measure provides a useful indicator for differentiating at-risk individuals and evaluating the efficacy of interventions, and it facilitates the investigation of 71 mechanisms of aging <sup>20</sup>. Here, with this validated aging measure, we tested the 72 hypothesis that lifestyle interventions impact health outcomes (CVD, cancer, and 73 mortality) via their effects on aging rates. We used data from the UK Biobank (UKB) 74 and the US National Health and Nutrition Examination Survey (NHANES), which 75 comprised nationally representative and large samples of participants in the UK and the 76 US. More specifically, this study aimed to examine: (1) the associations of unhealthy 77 lifestyles with aging; (2) the associations of aging with adverse health outcomes; and 78 (3) the mediating role of aging in the association of unhealthy lifestyles with adverse 79 health outcomes. 80

81

#### 82 **Results**

#### 83 **Population characteristics**

**Table 1** shows sex-specific characteristics of UKB (N= 405,944) and NHANES participants (N= 9,972), respectively. In UKB, the chronological age and PhenoAge of participants were 57.0 years (SD= 8.0) and 53.2 years (SD= 10.0); In NHANES, the chronological age and PhenoAge of participants were 49.6 years (SD= 17.6) and 43.3 years (SD= 19.8), respectively. In UKB, we recorded 29,726 incident CVD cases, 34,413 incident cancer cases, and 27,471 deaths during a mean follow-up of 11.9 years. In NHANES, we recorded 258 CVD deaths, 325 cancer deaths, and 1,374 all-cause

91 deaths during a mean follow-up of 9.8 years. The proportion of participants with

92 favorable, intermediate, and unfavorable lifestyles were 23.0%, 59.9%, and 17.1% in

93 UKB, and 24.4%, 66.4%, and 9.2% in NHANES, respectively. The distributions of

- 94 unhealthy lifestyle scores of UKB and NHANES were shown in Fig. S1 and Fig. S2.
- 95 Associations of unhealthy lifestyles with aging (Path a)
- 96 The unhealthy lifestyles score was positively associated with PhenoAgeAccel (UKB:
- 97 β=0.741± 0.008 SE, P<0.001; NHANES: β=0.874± 0.064 SE, P<0.001) (**Table S1**).
- 98 Associations of aging with adverse health outcomes (Path b)

99 PhenoAgeAccel was positively associated with the risk of adverse health outcomes in 100 both UKB and NHANES, as we observed in the previous study <sup>22</sup>. For instance, for 101 each one-year increase in PhenoAgeAccel, the risk of incident CVD, incident cancer, 102 and all-cause mortality increased by 4% (hazard ratios [HR]:1.04, 95% confidence 103 intervals [CIs]: 1.04, 1.05), 2% (HR: 1.02, 95%CI: 1.02, 1.02), and 7% (HR: 1.07, 104 95%CI: 1.07, 1.07), respectively in UKB (**Table S2**).

105 Mediations analysis of aging on associations of unhealthy lifestyles with adverse 106 health outcomes (Path c)

Table 2 presents the associations of unhealthy lifestyles with adverse health outcomes 107 and the mediation proportion of PhenoAgeAccel in adverse health outcomes attributed 108 to unhealthy lifestyles. In UKB, unhealthy lifestyles were significantly associated with 109 adverse health outcomes. When unfavorable lifestyles were compared with favorable 110 lifestyles, the risks of incident CVD, incident cancer, and all-cause mortality were 111 increased by 59% (HR: 1.59, 95%CI: 1.53, 1.65), 33% (HR: 1.33, 95%CI: 1.29, 1.38), 112 and 84% (HR: 1.84, 95%CI: 1.77, 1.92) in model 1, respectively. After further adjusting 113 114 PhenoAgeAccel in model 2, the magnitude of increased risk of incident CVD, incident cancer, and all-cause mortality was reduced. The mediation proportion of 115 PhenoAgeAccel in associations of unhealthy lifestyles with risk of incident CVD, 116 incident cancer, and all-cause mortality were 20.0%, 17.8%, and 26.6% (all P values < 117 0.001), respectively. 118

In NHANES, unhealthy lifestyles were significantly associated with adverse health 119 120 outcomes as well. Although the association of unhealthy lifestyles with the risk of CVD mortality was not statistically significant, effect sizes were broadly consistent with the 121 findings from NHANES and the analyses appear to be underpowered due to a small 122 number of cases in the favorable lifestyle group. Similarly, after further adjusting for 123 PhenoAgeAccel in model 2, the magnitude of increased risk of CVD mortality, cancer 124 mortality, and all-cause mortality was reduced. The mediation proportion of 125 PhenoAgeAccel in associations of lifestyles with risk of CVD mortality, cancer 126 mortality, and all-cause mortality were 43.9% (P values = 0.100), 25.7%, and 35.2% 127 (all P values < 0.05), respectively. 128

#### 129 Sensitivity analyses

First, using another aging measure—Biological Age Acceleration (BioAgeAccel), we observed similar results, but the mediation proportion of BioAgeAccel (ranging from 1.9% to 18.3% in UKB and 1.1% to 8.1% in NHANES) was smaller than that of PhenoAgeAccel (**Table S3-S7**). Second, the mediation proportion of PhenoAgeAccel in associations of lifestyles with incident CVD was slightly smaller in women than that

in men (P for interaction< 0.001). The above sex-specific results were not observed in</li>
NHANES (Table S6). Third, after excluding outcomes that occurred within the first
two years of follow-up, the association between unhealthy lifestyles and adverse health
outcomes was maintained and the mediation proportion of PhenoAgeAccel in
associations of lifestyles with adverse health outcomes did not change substantially
(Table S7). Fourth, the difference method showed similar results (Table S8).

141

#### 142 **Discussion**

Based on the two large population-based cohort studies, this study found that accelerated aging partially mediated the associations of unhealthy lifestyles with adverse health outcomes (CVD, cancer, and mortality) in the UK and US populations. The mediation proportion ranged from 17.8 % to 26.6% in UKB and 25.7% to 35.2% in NHANES. The findings reveal a novel pathway linking unhealthy lifestyles to adverse health outcomes and the potential for lifestyle intervention.

To our knowledge, studies investigating the mediating role of aging in the 149 association of lifestyles with adverse health outcomes are scarce, with one exception by 150 our group <sup>23</sup>. In this previous study of older Chinese adults, aging is suggested to 151 partially mediate the association of lifestyles with mortality. In the present study, we 152 enlarged the age range by including a large sample size of participants aged 40-69 years 153 154 old in UKB and 20-84 years old in NHANES. We further included incident CVD and cancer in UKB, and CVD mortality and cancer mortality in NHANES for adverse health 155 outcomes, because CVD and cancer are the leading causes of increased disability-156 adjusted life-years and mortality globally <sup>24,25</sup>. We extended our previous observation 157 to more general populations and more adverse health outcomes, enhancing the 158 significance of the findings in disease prevention and intervention. 159

The explanation of the mediating role of aging in the associations of unhealthy 160 lifestyles with CVD, cancer, and mortality might be related to inflammation/immunity. 161 First, unhealthy lifestyles, such as smoking, and obesity, are likely to contribute to 162 accelerated aging by triggering low-grade chronic inflammation <sup>26-28</sup>, which increases 163 individuals' susceptibility to diverse adverse outcomes. Second, PhenoAgeAccel is 164 found to be associated with increased activation of pro-inflammatory pathways (16). 165 Additionally, as blood biomarkers involved in PhenoAge could reflect individuals' 166 status of inflammation (i.e., C-reactive protein) and immune system (i.e., lymphocyte 167 percent, mean (red) cell volume, red cell distribution width, and white blood cell count), 168 PhenoAgeAccel could capture risks of multiple diseases from the preclinical 169 perspective. Genes linked to PhenoAgeAccel are overrepresented in the immune system, 170 carbohydrate homeostasis pathways, and cell function, suggesting that the effect of 171 unhealthy lifestyles on accelerated aging may be through multiple pathways including 172 inflammation/immune pathways (17). Third, inflammation and dysfunctional immune 173 function contribute to the pathogenesis of multiple diseases, such as CVD and cancer, 174 which eventually contribute to death <sup>29,30</sup>. Based on the evidence above, we speculate 175 that unhealthy lifestyles lead to the pathogenesis of disease through accelerated aging 176 (unhealthy lifestyles  $\rightarrow$  accelerated aging (inflammation and immune dysfunction)  $\rightarrow$ 177 adverse health outcomes). 178

Using another aging measure—BioAgeAccel, we observed similar results though 179 with weaker effect sizes, which enhanced our speculation that aging partially mediated 180 the associations of unhealthy lifestyles with CVD, cancer, and mortality. Researchers 181 revealed that genes linked to BioAgeAccel were enriched in lipid-related pathways <sup>31</sup> 182 which were reported to be associated with the regulation of aging and longevity <sup>20</sup>. 183 Since dysregulation in lipid metabolism is another prominent pathway in the 184 pathogenesis of CVD and cancer <sup>32,33</sup>, there may be another pathway that unhealthy 185 lifestyles lead to the pathogenesis of disease through aging (unhealthy lifestyles  $\rightarrow$ 186 accelerated aging (lipid metabolism)  $\rightarrow$  adverse health outcomes). The mutual 187 verification of the mediating role of aging by two aging measures further tells us that if 188 more aging measures are available, we could capture aging more comprehensively. 189 Many aging measures are under development, involving a single hallmark of aging (eg, 190 DNA methylation)<sup>34</sup> or composite aging measures by integrating multi-omics data<sup>35</sup>. 191 Hence, we have the opportunity to further understand the important role of aging, a 192 complex process, in the pathway linking unhealthy lifestyles to adverse health 193 outcomes. Future studies are needed to validate our findings using more aging measures. 194

The associations of unhealthy lifestyles with CVD, cancer, and mortality observed 195 in this study highlight the potential of multi-domain lifestyle interventions (i.e., healthy 196 diet, no smoking, no alcohol consumption, regular exercise, and healthy BMI) in 197 disease prevention. As the implementation of multi-domain interventions in preventing 198 cognitive decline and frailty has been suggested to be effective <sup>9-11</sup>, it is meaningful to 199 extend such interventions to CVD, cancer, and even aging itself. Besides, from the point 200 of view of pharmacological intervention, many anti-aging drugs have been developed 201 such as caloric restriction mimetics (resveratrol, rapamycin, metformin), senolytics, and 202 synthetic sirtuin activators, which are promising to alleviate or delay age-related 203 conditions <sup>36-40</sup>. With a more comprehensive understanding of aging hallmarks, more 204 aging interventions are expected to flourish. Likewise, advances in biomedical research 205 may bring us the possibility of anti-aging and delaying the onset of diseases in the future. 206

We caution that it would premature to interpret our results as showing that lifestyle 207 interventions reduce adverse health outcomes by slowing aging. While PhenoAge and 208 BioAge well-validated metrics related to the aging process, their precise interpretation 209 as metrics of aging is complicated by the lack of consensus on what aging is  $^{41,42}$ . For 210 example, it is possible that many of the adverse health outcomes observed today are a 211 result of the cumulative impact of industrialized lifestyles over decades, and not of the 212 basic human biology of aging. In that case, PhenoAge and BioAge might at least 213 partially reflect these aging-independent lifestyle impacts, and we could still see the 214 215 relationships observed here. At a practical level, such nuances could be important to disentangle mechanisms and help tailor interventions to specific aspects of aging and/or 216 health that are most important for preventing adverse outcomes. 217

The strengths of our study included the large sample sizes of middle-aged and older adults from the UK and the US and the use of two well-validated aging measures. Nevertheless, several limitations should be noted. First, the assessment of lifestyle was based on self-reported information and could be subject to bias. Second, the UKB and NHANES participants are healthier than the general population and are mostly

Caucasian. Hence, our findings may not be generalizable to other populations. Third,
there was likely residual confounding even though we controlled for various covariates.
Future studies are needed to further validate our findings in other populations and to
develop appropriate lifestyle interventions and geroprotective programs.

This study, for the first time, demonstrated that accelerated aging partially mediated the associations of unhealthy lifestyles with CVD, cancer, and mortality in UK and US populations. The findings reveal a novel pathway and the potential of geroprotective programs in mitigating health inequality in late-life beyond lifestyle interventions.

#### 232 Methods

231

#### 233 Study population

UKB, a prospective, population-based study, recruited more than 500,000 participants 234 aged 40-69 years from 22 assessment centers across the UK from 2006 to 2010. Details 235 of the study design and data collection have been described previously <sup>43</sup>. UKB was 236 approved by the North West Multi-center Research Ethics Committee <sup>44</sup>, and written 237 informed consent was obtained from all participants <sup>45</sup>. Among 499,366 participants 238 aged 40-69 years old, we excluded those with missing information on lifestyle factors 239 (N=432), clinical blood biomarkers (N=85,193), and covariates (N=7,797). Finally, 240 we included 405,944 participants for all-cause mortality (Analytic sample 1). We 241 242 further excluded participants with CVD at baseline (N=27,236) and cancer at baseline (N=33,741). We included 378,708, and 372,203 participants for the analyses of incident 243 CVD (Analytic sample 2), and incident cancer (Analytic sample 3), respectively. 244

NHANES uses a multistage, complex probability design to recruit a representative 245 246 sample of community-dwelling children and adults of the US population. Since 1999, NHANES has become a continuous biennial survey. Approximately 5,000 participants 247 among the 7,000 randomly selected individuals were invited to complete both the 248 249 questionnaire interview and comprehensive health examination. NHANES was approved by the National Center for Health Statistics Research Ethics Review Board, 250 and written informed consent was obtained from all participants. Detailed information 251 available through the 252 on the NHANES is NHANES website (https://www.cdc.gov/nchs/nhanes/index.htm)<sup>46</sup>. Among 60,685 participants who were 253 not pregnant and aged 20 years and older from the continuous NHANES (1999-2010) 254 surveys, we excluded those with missing information on clinical blood biomarkers (N= 255 49,698) and covariates (N= 1,015). Overall, we included 9,972 participants for the 256 analysis of CVD mortality, cancer mortality, and all-cause mortality. The flow chart is 257 shown in Fig. 1. 258

#### 259 Assessments of lifestyles

260 Consistent with the recommendations from World Health Organization <sup>47</sup>, we 261 constructed an unhealthy lifestyles score, including five lifestyle factors (smoking, 262 drinking, physical inactivity, unhealthy body mass index (BMI), and unhealthy diet) 263 assessed at baseline by a touchscreen questionnaire in UKB and NHANES. In UKB, 264 structured questionnaires and 24-hour dietary recalls offered information on all lifestyle 265 factors. An unhealthy level of smoking was defined as participants who reported ever 266 smoked or current smoking or who had smoked more than 100 times in their life.

Drinking was defined as participants who reported alcohol consumption of more than 267 one drink for women and two drinks for men according to the UK dietary guidelines <sup>48</sup> 268 (one drink contains ethanol 8 g in the UK). Diet was defined based on the ideal intake 269 of dietary components for cardiovascular health <sup>49</sup>. An unhealthy diet was defined as an 270 intake of less than half of the following diet components and not meeting the amount 271 272 of intake requirements: increased intake of vegetables, fruits, (shell) fish, wholes grains, dairy products, and vegetable oils; and no intake of sugar-sweetened beverages; and 273 reduced intake of refined grains, processed meats, and unprocessed red meats according 274 to the previous study <sup>50</sup>. Physical inactivity was defined as less than 75 minutes of 275 vigorous activity per week or 150 minutes of moderate activity per week (or an 276 equivalent combination) or engaging in vigorous activity less than once a week or 277 moderate activity less than 5 days a week <sup>51</sup>. In NHANES, smoking was defined as 278 participants who reported ever smoking more than 100 cigarettes <sup>52</sup>. Using self-reported 279 frequency and volume of alcohol consumption, drinking was defined as daily alcohol 280 consumption of more than one drink for women and one drink for men, according to 281 the US dietary guidelines <sup>53</sup> (one drink contains 14 g of ethanol in the US). According 282 to the questionnaires, the metabolic equivalent scores were calculated. Participants 283 were classified into thirds and they were defined as physical inactivity if their metabolic 284 equivalent score was lower than the top third of the distribution <sup>52</sup>. Dietary quality was 285 assessed by the Healthy Eating Index-2010 (HEI-2010), a measurement score to 286 evaluate the degree to which diets met the 2010 Dietary Guidelines for Americans. The 287 total score ranged from 0 to 100 and a higher score indicated a healthier diet <sup>54</sup>. 288 According to a previous study, we defined an unhealthy diet as the HEI in the three 289 lowest quintiles of distribution <sup>52</sup>. In both UKB and NHANES, an unhealthy BMI was 290 291 defined as a BMI out of the range of  $18.5-24.9 \text{ kg/m}^2$ .

For every single lifestyle, we assigned 1 point and 0 points for an unhealthy level and a healthy level, respectively. The unhealthy lifestyles score was the sum of the points and ranged from 0 to 5, with higher scores indicating a higher level of an unhealthy lifestyle. The unhealthy lifestyles score was subsequently categorized as favorable (score: 0 to 1), intermediate (score: 2 to 3), and unfavorable (score: 4 to 5) lifestyles.

#### 298 Aging measures

PhenoAgeAccel was previously developed and validated using data from NHANES <sup>19,22</sup> and has been applied to UKB participants in our recent work <sup>20</sup>. Briefly, nine biomarkers (i.e., albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red blood cell distribution width, alkaline phosphatase, white blood cell count) and chronological age collected at baseline were used to calculate PhenoAge (in years), with the equation as follows:

305 PhenoAge = 
$$141.50 + \frac{\ln\{-0.00553 \times \ln(1 - \text{mortality risk})\}}{0.090165}$$

306 where

307 Mortality risk =  $1 - \exp(\frac{-1.51714 \times \exp(xb)}{0.0076927})$ 

308 and

| 309 | $xb = -19.907 - 0.0336 \times albumin + 0.0095 \times creatinine + 0.1953 \times glucose$ |
|-----|---|
|     |   |

- 310  $+ 0.0954 \times \ln(C \text{reactive protein}) 0.0120$
- 311  $\times$  lymphocyte percentage + 0.0268  $\times$  mean cell volume
  - $+ 0.3306 \times \text{red}$  blood cell distribution width + 0.00188
- 313 × alkaline phosphatase +  $0.0554 \times$  white blood cell count
- $+ 0.0804 \times \text{chronological age}$

PhenoAgeAccel was calculated as a residual from a linear regression of PhenoAge
 against chronological age <sup>20,22</sup>.

#### 317 Ascertainment of adverse health outcome

In UKB, the outcomes - incident CVD, incident cancer, and all-cause mortality - were 318 ascertained through linked hospital admissions data through Aug 29, 2021. We used the 319 320 International Statistical Classification of Diseases and Related Health Problems 9th 321 (ICD-9) (410, 411, 412, 413, 414, 429.79, 430, 431, 432, 433, 434, 435, 436, 437, and 438) and 10th (ICD-10) (I20, I21, I22, I23, I24.1, I25, I46, I60, I61, I63, and I64) to 322 define CVD 55. Participants' time to CVD was calculated from baseline to the date of 323 the first diagnosis of CVD, date of death, date of loss to follow-up, or Aug 29, 2021, 324 whichever came first. Cancer and deaths were ascertained through the NHS Information 325 Centre (England and Wales) and the NHS Central Register (Scotland). We used ICD-9 326 (140-208, except 173) and ICD-10 (C00-C96, except C44) to define the diagnosis of 327 cancer. Participants' time to cancer was calculated from baseline to the date of the first 328 diagnosis of cancer, date of death, date of loss to follow-up, or 30 Nov 2020, whichever 329 came first. Participants' time to death was calculated from baseline to the date of death, 330 date of loss to follow up, or 8 Apr 2021, whichever came first. 331

In NHANES, CVD mortality, cancer mortality, and all-cause mortality during follow-up were based on linked data from records taken from the National Death Index through December 31, 2015, provided through the Centers for Disease Control and Prevention.

#### 336 Covariates

312

We considered the following covariates through questionnaires, i.e., age, sex, race/ 337 ethnicity, education level, occupational status (UKB only), Townsend deprivation index 338 (TDI) (UKB only), marital status (NHANES only), and family poverty income ratio 339 (PIR) (NHANES only). The self-reported race/ ethnicity was categorized as White, 340 Mixed background, Asian, Black, Chinese, and Others in UKB; Mexican American, 341 Non-Hispanic White, Non-Hispanic Black, and others in NHANES. Education level 342 was categorized as high (college or university degree), intermediate (A/AS levels or 343 equivalent, O levels/GCSEs or equivalent), and low (none of the aforementioned) in 344 UKB <sup>56</sup>; college, some college, high school (HS), and less than HS /general educational 345 diploma (GED) in NHANES<sup>22</sup>. Occupation status was categorized as working, retired, 346 and others. TDI was calculated by combining information on employment, social class, 347 housing, and car availability. A lower score on TDI indicates a higher level of 348 socioeconomic status. PIR (categorized as < 1.3, 1.30-3.50, and >3.50) was estimated 349 using guidelines and adjustments for family size, year, and state <sup>57</sup>. 350

#### 351 Statistical analysis

352 The basic characteristics of the study participants were summarized by sex using mean

and standard deviation (SD) for continuous variables and number (percentage) for categorical variables. Basic characteristics by sex were compared using the analysis of variance (ANOVA) or  $\chi^2$  test.

To evaluate the potential mediating role of PhenoAgeAccel in the association of 356 unhealthy lifestyles with adverse health outcomes, we considered three pathways (a: 357 358 unhealthy lifestyles  $\rightarrow$  aging; b: aging  $\rightarrow$  adverse health outcomes; c: unhealthy lifestyles  $\rightarrow$  adverse health outcomes. Fig. 2). For path a, general linear regression 359 models were used to investigate the associations of unhealthy lifestyle scores with 360 PhenoAgeAccel. The coefficient  $(\beta)$  and standard error (SE) were documented in model 361 1. According to previous studies <sup>22,52</sup>, model 1 included chronological age, gender, 362 education level, race, occupational status (UKB only), TDI (UKB only), marital status 363 (NHANES only), and PIR (NHANES only). For path b, Cox proportional hazards 364 365 regression models were performed to investigate the associations of PhenoAgeAccel with adverse health outcomes. The HR and 95% CI were documented in model 1. For 366 path c, Cox proportional hazards regression models were used to estimate the HR and 367 95% CIs of adverse health outcomes associated with unhealthy lifestyles and aging in 368 model 1 and model 2 (additionally including PhenoAgeAccel based on model 1). To 369 370 determine whether PhenoAgeAccel mediated the associations of unhealthy lifestyles with adverse health outcomes, the formal mediation analyses were performed to 371 estimate the mediation proportions and 95% CIs in model 1<sup>58</sup>. 372

We performed several sensitivity analyses to test the robustness of our results. First, 373 we repeated all the analyses using another aging measure—BioAgeAccel in model 1 374 and model 3 (additionally included BioAgeAccel based on model 1). Details on 375 BioAgeAccel were shown in supplemental methods. Second, given the sex difference 376 in aging and health, we further conducted a stratified analysis by sex to investigate the 377 associations of unhealthy lifestyles with adverse health outcomes and the mediation 378 379 proportion of aging in adverse health outcomes attributed to unhealthy lifestyles. Third, to reduce the potential reverse causation, we repeated the main analyses after excluding 380 outcomes that occurred within the first two years of follow-up. Forth, we repeated the 381 main analyses using the difference method <sup>59</sup> to evaluate the mediating role of 382 PhenoAgeAccel. 383

All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and R version 3.6.3 (2020-02-29). We considered a two-sided P value <0.05 to be statistically significant.

#### 387 Data availability

Data and materials are available via UK Biobank at http://www.ukbiobank.ac.uk/. Data
from the US National Health and Nutrition Examination Survey (NHANES) are
available at the NHANES website: https://www.cdc.gov/nchs/nhanes/index.htm.

#### 391 **Code availability**

- 392 The source code for this study can be obtained upon request to the corresponding
- 393 author (Prof. Z.L., Zuyun.liu@outlook.com)
- 394

#### **Reference:** 395 Kraus, W. E. et al. Physical Activity, All-Cause and Cardiovascular Mortality, 1 396 and Cardiovascular Disease. Med Sci Sports Exerc 51, 1270-1281, 397 doi:10.1249/mss.000000000001939 (2019). 398 Chareonrungrueangchai, K., Wongkawinwoot, K., Anothaisintawee, T. & 2 399 400 Reutrakul, S. Dietary Factors and Risks of Cardiovascular Diseases: An Umbrella Review. Nutrients 12, doi:10.3390/nu12041088 (2020). 401 Thurber, K. A. et al. Tobacco smoking and mortality among Aboriginal and 3 402 Torres Strait Islander adults in Australia. Int J Epidemiol 50, 942-954, 403 doi:10.1093/ije/dyaa274 (2021). 404 Livingstone, K. M., Abbott, G., Ward, J. & Bowe, S. J. Unhealthy Lifestyle, 405 4 Genetics and Risk of Cardiovascular Disease and Mortality in 76,958 406 407 Individuals from the UK Biobank Cohort Study. Nutrients 13, doi:10.3390/nu13124283 (2021). 408 Shan, Z. et al. Rotating night shift work and adherence to unhealthy lifestyle in 5 409 predicting risk of type 2 diabetes: results from two large US cohorts of female 410 nurses. Bmj 363, k4641, doi:10.1136/bmj.k4641 (2018). 411 Martinez, J. E. et al. Unhealthy Lifestyle and Gut Dysbiosis: A Better 6 412 Understanding of the Effects of Poor Diet and Nicotine on the Intestinal 413 Microbiome. Front Endocrinol (Lausanne) 12, 667066, 414 doi:10.3389/fendo.2021.667066 (2021). 415 Zhang, Y. B. et al. Combined lifestyle factors, all-cause mortality and 7 416 cardiovascular disease: a systematic review and meta-analysis of prospective 417 cohort studies. J Epidemiol Community Health 75, 92-99, doi:10.1136/jech-418 2020-214050 (2021). 419 Zhang, Y. B. et al. Combined lifestyle factors, incident cancer, and cancer 8 420 mortality: a systematic review and meta-analysis of prospective cohort studies. 421 Br J Cancer 122, 1085-1093, doi:10.1038/s41416-020-0741-x (2020). 422 Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive 423 9 training, and vascular risk monitoring versus control to prevent cognitive 424 decline in at-risk elderly people (FINGER): a randomised controlled trial. 425 Lancet 385, 2255-2263, doi:10.1016/s0140-6736(15)60461-5 (2015). 426 Chew, K. A. et al. SINgapore GERiatric intervention study to reduce physical 10 427 frailty and cognitive decline (SINGER)-pilot: A feasibility study. Alzheimers 428 Dement (N Y) 7, e12141, doi:10.1002/trc2.12141 (2021). 429 11 Hazuda, H. P. et al. Association of Intensive Lifestyle and Metformin 430 Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. 431 J Gerontol A Biol Sci Med Sci 76, 929-936, doi:10.1093/gerona/glaa295 (2021). 432 Sierra, F. & Kohanski, R. Geroscience and the trans-NIH Geroscience Interest 12 433 Group, GSIG. Geroscience 39, 1-5, doi:10.1007/s11357-016-9954-6 (2017). 434 Ryan, J., Wrigglesworth, J., Loong, J., Fransquet, P. D. & Woods, R. L. A 435 13 Systematic Review and Meta-analysis of Environmental, Lifestyle, and Health 436 Factors Associated With DNA Methylation Age. J Gerontol A Biol Sci Med Sci 437 75, 481-494, doi:10.1093/gerona/glz099 (2020). 438

Robinson, O. et al. Determinants of accelerated metabolomic and epigenetic 14 439 aging in a UK cohort. Aging Cell 19, e13149, doi:10.1111/acel.13149 (2020). 440 Zhao, W. et al. Education and Lifestyle Factors Are Associated with DNA 15 441 Methylation Clocks in Older African Americans. Int J Environ Res Public 442 Health 16, doi:10.3390/ijerph16173141 (2019). 443 444 16 McCartney, D. L. et al. Epigenetic prediction of complex traits and death. Genome Biol 19, 136, doi:10.1186/s13059-018-1514-1 (2018). 445 Quach, A. et al. Epigenetic clock analysis of diet, exercise, education, and 17 446 lifestyle factors. Aging (Albany NY) 9, 419-446, doi:10.18632/aging.101168 447 (2017). 448 18 Fiorito, G. et al. Socioeconomic position, lifestyle habits and biomarkers of 449 epigenetic aging: a multi-cohort analysis. Aging (Albany NY) 11, 2045-2070, 450 doi:10.18632/aging.101900 (2019). 451 Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and 19 452 healthspan. Aging (Albany NY) 10, 573-591, doi:10.18632/aging.101414 (2018). 453 Kuo, C. L., Pilling, L. C., Liu, Z., Atkins, J. L. & Levine, M. E. Genetic 20 454 associations for two biological age measures point to distinct aging phenotypes. 455 Aging Cell 20, e13376, doi:10.1111/acel.13376 (2021). 456 21 Levine, M. E. Modeling the rate of senescence: can estimated biological age 457 predict mortality more accurately than chronological age? J Gerontol A Biol Sci 458 Med Sci 68, 667-674, doi:10.1093/gerona/gls233 (2013). 459 Liu, Z. et al. A new aging measure captures morbidity and mortality risk across 22 460 diverse subpopulations from NHANES IV: A cohort study. PLoS Med 15, 461 e1002718, doi:10.1371/journal.pmed.1002718 (2018). 462 23 Jin, S. et al. Association of lifestyle with mortality and the mediating role of 463 aging among older adults in China. Arch Gerontol Geriatr 98, 104559, 464 doi:10.1016/j.archger.2021.104559 (2022). 465 24 Joseph, P. et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: 466 467 The Epidemiology and Risk Factors. Circ Res 121, 677-694, doi:10.1161/circresaha.117.308903 (2017). 468 Leong, D. P. et al. Reducing the Global Burden of Cardiovascular Disease, Part 25 469 2: Prevention and Treatment of Cardiovascular Disease. Circ Res 121, 695-710, 470 doi:10.1161/circresaha.117.311849 (2017). 471 Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and 472 26 metabolic disease. J Clin Invest 127, 1-4, doi:10.1172/jci92035 (2017). 473 27 Strzelak, A., Ratajczak, A., Adamiec, A. & Feleszko, W. Tobacco Smoke 474 Induces and Alters Immune Responses in the Lung Triggering Inflammation, 475 Allergy, Asthma and Other Lung Diseases: A Mechanistic Review. Int J Environ 476 Res Public Health 15, doi:10.3390/ijerph15051033 (2018). 477 Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu 478 28 Rev Med 62, 141-155, doi:10.1146/annurev-med-042909-093756 (2011). 479 Frostegård, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 480 29 11, 117, doi:10.1186/1741-7015-11-117 (2013). 481 30 Greten, F. R. & Grivennikov, S. I. Inflammation and Cancer: Triggers, 482

| 484   |                | Mechanisms, and Consequences. Immunity 51, 27-41,   |
|---|----------------|---|
| 404   |                | doi:10.1016/j.immuni.2019.06.025 (2019).  |
| 485   | 31             | Mutlu, A. S., Duffy, J. & Wang, M. C. Lipid metabolism and lipid signals in   |
| 486   |                | aging and longevity. Dev Cell 56, 1394-1407, doi:10.1016/j.devcel.2021.03.034   |
| 487   |                | (2021).   |
| 488   | 32             | Deprince, A., Haas, J. T. & Staels, B. Dysregulated lipid metabolism links  |
| 489   |                | NAFLD to cardiovascular disease. Mol Metab 42, 101092,  |
| 490   |                | doi:10.1016/j.molmet.2020.101092 (2020).  |
| 491   | 33             | Bian, X. et al. Lipid metabolism and cancer. J Exp Med 218,   |
| 492   |                | doi:10.1084/jem.20201606 (2021).  |
| 493   | 34             | Porter, H. L. et al. Many chronological aging clocks can be found throughout  |
| 494   |                | the epigenome: Implications for quantifying biological aging. Aging Cell 20,  |
| 495   |                | e13492, doi:10.1111/acel.13492 (2021).  |
| 496   | 35             | Nie, C. et al. Distinct biological ages of organs and systems identified from a   |
| 497   |                | multi-omics study. Cell Rep 38, 110459, doi:10.1016/j.celrep.2022.110459  |
| 498   |                | (2022).   |
| 499   | 36             | Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J  |
| 500   |                | Intern Med 288, 518-536, doi:10.1111/joim.13141 (2020).   |
| 501   | 37             | Statzer, C. et al. Youthful and age-related matreotypes predict drugs promoting   |
| 502   |                | longevity. Aging Cell 20, e13441, doi:10.1111/acel.13441 (2021).  |
| 503   | 38             | Palliyaguru, D. L., Moats, J. M., Di Germanio, C., Bernier, M. & de Cabo, R.  |
| 504   |                | Frailty index as a biomarker of lifespan and healthspan: Focus on   |
| 505   |                | pharmacological interventions. Mech Ageing Dev 180, 42-48,  |
| 506   |                | doi:10.1016/j.mad.2019.03.005 (2019).   |
| 507   | 39             | Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M. & Markowicz-Piasecka,  |
| гоо   |                |   |
| 508   |                | M. Is metformin a geroprotector? A peek into the current clinical and   |
| 508<br>509  |                | M. Is metformin a geroprotector? A peek into the current clinical and experimental data. <i>Mech Ageing Dev</i> <b>191</b> , 111350,  |
|   |                |   |
| 509   | 40             | experimental data. Mech Ageing Dev 191, 111350,   |
| 509<br>510  | 40             | experimental data. <i>Mech Ageing Dev</i> <b>191</b> , 111350, doi:10.1016/j.mad.2020.111350 (2020).  |
| 509<br>510<br>511   | 40             | experimental data. <i>Mech Ageing Dev</i> <b>191</b> , 111350,<br>doi:10.1016/j.mad.2020.111350 (2020).<br>Le Pelletier, L. <i>et al.</i> Metformin alleviates stress-induced cellular senescence of  |
| 509<br>510<br>511<br>512  | 40<br>41       | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife</li> </ul>  |
| 509<br>510<br>511<br>512<br>513   |                | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> </ul>  |
| 509<br>510<br>511<br>512<br>513<br>514  |                | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515   |                | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global</li> </ul>  |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516  |                | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517   | 41             | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518                                    | 41             | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"? Mech Ageing Dev 192, 111344, doi:10.1016/j.mad.2020.111344 (2020).</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518<br>519                             | 41<br>42       | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"?</li> </ul>  |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518<br>519<br>520                      | 41<br>42       | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"? Mech Ageing Dev 192, 111344, doi:10.1016/j.mad.2020.111344 (2020).</li> <li>Sudlow, C. et al. UK biobank: an open access resource for identifying the causes</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518<br>519<br>520<br>521               | 41<br>42       | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"? Mech Ageing Dev 192, 111344, doi:10.1016/j.mad.2020.111344 (2020).</li> <li>Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12,</li> </ul>   |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518<br>519<br>520<br>521<br>522        | 41<br>42<br>43 | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"? Mech Ageing Dev 192, 111344, doi:10.1016/j.mad.2020.111344 (2020).</li> <li>Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779, doi:10.1371/journal.pmed.1001779 (2015).</li> </ul>  |
| 509<br>510<br>511<br>512<br>513<br>514<br>515<br>516<br>517<br>518<br>519<br>520<br>521<br>522<br>523 | 41<br>42<br>43 | <ul> <li>experimental data. Mech Ageing Dev 191, 111350, doi:10.1016/j.mad.2020.111350 (2020).</li> <li>Le Pelletier, L. et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 10, doi:10.7554/eLife.62635 (2021).</li> <li>Cohen, A. A. et al. Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mech Ageing Dev 191, 111316, doi:10.1016/j.mad.2020.111316 (2020).</li> <li>Cohen, A. A., Legault, V. &amp; Fülöp, T. What if there's no such thing as "aging"? Mech Ageing Dev 192, 111344, doi:10.1016/j.mad.2020.111344 (2020).</li> <li>Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779, doi:10.1371/journal.pmed.1001779 (2015).</li> <li>Haan, M. N., Zeki Al-Hazzouri, A. &amp; Aiello, A. E. Life-span socioeconomic</li> </ul> |

| 527        | 45 | Li, Y., Xue, Q. L., Odden, M. C., Chen, X. & Wu, C. Linking early life risk                 |
|------------|----|---|
| 528        | 77 | factors to frailty in old age: evidence from the China Health and Retirement                |
| 520<br>529 |    | Longitudinal Study. Age Ageing 49, 208-217, doi:10.1093/ageing/afz160 (2020).               |
| 529<br>530 | 46 | Statistics., N. C. f. H. National Health and Nutrition Examination Survey.                  |
| 530<br>531 | 40 | Atlanta: Centers for Disease Control and Prevention. (2018 [cited 2018 Nov                  |
|            |    | · -   |
| 532        | 17 | 29]).<br>None W.S. et al. Albumin diabasis in aritically ill action to use surger anission. |
| 533        | 47 | Yang, W. S. <i>et al.</i> Albumin dialysis in critically ill patients: use versus omission  |
| 534        |    | of intradialytic heparin. Artificial organs <b>32</b> , 411-416, doi:10.1111/j.1525-        |
| 535        | 40 | 1594.2008.00560.x (2008).   |
| 536        | 48 | Bik, W. <i>et al.</i> The relationship between adiponectin levels and metabolic status      |
| 537        |    | in centenarian, early elderly, young and obese women. <i>Neuro endocrinology</i>            |
| 538        | 10 | <i>letters</i> <b>27</b> , 493-500 (2006).  |
| 539        | 49 | Mozaffarian, D. Dietary and Policy Priorities for Cardiovascular Disease,                   |
| 540        |    | Diabetes, and Obesity: A Comprehensive Review. Circulation 133, 187-225,                    |
| 541        |    | doi:10.1161/circulationaha.115.018585 (2016).   |
| 542        | 50 | Said, M. A., Verweij, N. & van der Harst, P. Associations of Combined Genetic               |
| 543        |    | and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the                |
| 544        |    | UK Biobank Study. JAMA Cardiol 3, 693-702,  |
| 545        |    | doi:10.1001/jamacardio.2018.1717 (2018).  |
| 546        | 51 | Lloyd-Jones, D. M. et al. Defining and setting national goals for cardiovascular            |
| 547        |    | health promotion and disease reduction: the American Heart Association's                    |
| 548        |    | strategic Impact Goal through 2020 and beyond. Circulation 121, 586-613,                    |
| 549        |    | doi:10.1161/circulationaha.109.192703 (2010).   |
| 550        | 52 | Zhang, Y. B. et al. Associations of healthy lifestyle and socioeconomic status              |
| 551        |    | with mortality and incident cardiovascular disease: two prospective cohort                  |
| 552        |    | studies. Bmj 373, n604, doi:10.1136/bmj.n604 (2021).  |
| 553        | 53 | Phillips, J. A. Dietary Guidelines for Americans, 2020-2025. Workplace Health               |
| 554        |    | Saf 69, 395, doi:10.1177/21650799211026980 (2021).  |
| 555        | 54 | Kinderknecht, K., Harris, C. & Jones-Smith, J. Association of the Healthy,                  |
| 556        |    | Hunger-Free Kids Act With Dietary Quality Among Children in the US National                 |
| 557        |    | School Lunch Program. Jama 324, 359-368, doi:10.1001/jama.2020.9517                         |
| 558        |    | (2020).   |
| 559        | 55 | Wan, E. Y. F. et al. Blood Pressure and Risk of Cardiovascular Disease in UK                |
| 560        |    | Biobank: A Mendelian Randomization Study. Hypertension 77, 367-375,                         |
| 561        |    | doi:10.1161/HYPERTENSIONAHA.120.16138 (2021).   |
| 562        | 56 | Chadeau-Hyam, M. et al. Education, biological ageing, all-cause and cause-                  |
| 563        |    | specific mortality and morbidity: UK biobank cohort study. EClinicalMedicine                |
| 564        |    | <b>29-30</b> , 100658, doi:10.1016/j.eclinm.2020.100658 (2020).                             |
| 565        | 57 | Lehmler, H. J., Simonsen, D., Liu, B. & Bao, W. Environmental exposure to                   |
| 566        |    | pyrethroid pesticides in a nationally representative sample of U.S. adults and              |
| 567        |    | children: The National Health and Nutrition Examination Survey 2007-2012.                   |
| 568        |    | Environ Pollut 267, 115489, doi:10.1016/j.envpol.2020.115489 (2020).                        |
| 569        | 58 | Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. mediation: R                    |
| 570        |    | Package for Causal Mediation Analysis. <i>J Stat Softw</i> <b>59</b> (2014).                |
| 2.0        |    |   |

## 571 59 Nevo, D., Liao, X. & Spiegelman, D. Estimation and Inference for the

572 Mediation Proportion. Int J Biostat 13, doi:10.1515/ijb-2017-0006 (2017).

Acknowledgments: This research has been conducted using the UK Biobank resource 574 under application number 61856. We wish to acknowledge all participants of the UK 575 Biobank and US National Health and Nutrition Examination Survey (NHANES). This 576 research was supported by a grant from the National Natural Science Foundation of 577 China (82171584), the Fundamental Research Funds for the Central Universities, Key 578 579 Laboratory of Intelligent Preventive Medicine of Zhejiang Province (2020E10004), and Zhejiang University Global Partnership Fund (188170-11103). This work was also 580 supported by the Career Development Award (K01AG053408) from the National 581 Institute on Aging; Claude D. Pepper Older Americans Independence Center at Yale 582 School of Medicine, funded by the National Institute on Aging (P30AG021342). The 583 funders had no role in the study design; data collection, analysis, or interpretation; in 584 the writing of the report; or in the decision to submit the article for publication. 585

#### 586 Author contributions

587 Z.L. contributed to the concept and design of the research. X.L. contributed to data

- 588 analyses. X.L., X.C., J.Z., J.F., M.M., D., X.S., G.Y., Z.Y., C.L.K., X.Cheng., A.A.C.,
- and Z.L. contributed to interpretation of data. X.L., X.C., and J.Z. contributed to the
- drafting of the manuscript. X.C., J.Z., J.F., M.M., D., X.S., G.Y., Z.Y., C.L.K., X.Cheng.,
- A.A.C., and Z.L. contributed to critical revision of the manuscript. All authors read and
- approved the final version of the manuscript.

#### 593 **Competing Interest Statement**

594 The authors declare no competing interests.

# 596 Table 1. Baseline characteristics of participants from UK Biobank (UKB) and US National Health and Nutrition Examination Survey

597 (NHANES).

| Characteristics                        | Total          | Women          | Men            | P value |
|--|----------------|----------------|----------------|---------|
| UKB                                    |                |                |                |         |
|  | (N=405,944)    | (N=218,528)    | (N=187,416)    |         |
| Chronological age in years,<br>Mean±SD | 57.0±8.0       | 56.8±7.9       | 57.1±8.1       | < 0.001 |
| Race/ethnicity, n (%)                  |                |                |                | < 0.001 |
| White                                  | 385,421 (94.9) | 207,622 (95.0) | 177,799 (94.9) |         |
| Mixed                                  | 2,364 (0.6)    | 1,463 (0.7)    | 901 (0.5)      |         |
| South Asian                            | 7,367 (1.8)    | 3,290 (1.5)    | 4,077 (2.2)    |         |
| Black                                  | 6,087 (1.5)    | 3,441 (1.6)    | 2,646 (1.4)    |         |
| Chinese                                | 1,197 (0.3)    | 750 (0.3)      | 447 (0.2)      |         |
| Others                                 | 3,508 (0.9)    | 1,962 (0.9)    | 1,546 (0.8)    |         |
| TDI, Mean± SD                          | -1.3±3.1       | -1.4±3.0       | -1.3±3.1       | 0.01    |
| Education level, n (%)                 |                |                |                | < 0.001 |
| High                                   | 140,280 (34.6) | 71,734 (32.8)  | 68,546 (36.6)  |         |
| Intermediate                           | 132,828 (32.7) | 78,021 (35.7)  | 54,807 (29.2)  |         |
| Low                                    | 132,836 (32.7) | 68,773 (31.5)  | 64,063 (34.2)  |         |
| Occupation status, n (%)               |                |                |                | < 0.001 |
| Working                                | 235,655 (58.1) | 120,882 (55.3) | 114,773 (61.2) |         |
| Retired                                | 134,133 (33.0) | 76,294 (34.9)  | 57,839 (30.9)  |         |
| Other                                  | 36,156 (8.9)   | 21,352 (9.8)   | 14,804 (7.9)   |         |
| Smoking, yes, n (%)                    | 179,506 (44.9) | 83,547 (38.9)  | 95,959 (51.8)  | < 0.001 |
| Drinking, yes, n (%)                   | 147,559 (42.6) | 80,280 (44.9)  | 67,279 (40.1)  | < 0.001 |
| Physical inactivity, yes, n (%)        | 106,264 (26.7) | 60,562 (28.3)  | 45,702 (24.8)  | < 0.001 |

| Unhealthy diet, yes, n (%)        | 255,648 (63.0) | 128,229 (58.7) | 127,419 (68.0) | < 0.001 |
|-----------------------------------|----------------|----------------|----------------|---------|
| Unhealthy BMI, yes, n (%)         | 276,778 (68.4) | 134,697 (61.8) | 142,081 (76.1) | < 0.001 |
| Unhealthy lifestyles <sup>a</sup> |                |                |                | < 0.001 |
| Favorable                         | 93,491 (23.0)  | 59,754 (27.3)  | 33,737 (18.0)  |         |
| Intermediate                      | 243,161 (59.9) | 128,617 (58.9) | 114,544 (61.1) |         |
| Unfavorable                       | 692,92 (17.1)  | 30,157 (13.8)  | 39,135 (20.9)  |         |
| PhenoAge, Mean±SD                 | 53.3±10.0      | 52.2±9.5       | 54.4±10.5      | < 0.001 |
| NHANES                            |                |                |                |         |
|                                   | (N=9,972)      | (N=5,099)      | (N=4,873)      | P Value |
| Chronological age in years,       | 49.6±17.6      | 49.5±17.7      | 49.7±17.5      | 0.567   |
| Mean±SD                           | 49.0±1/.0      | 49.J±1/./      | 47./±1/.J      | 0.307   |
| Race/ethnicity, n (%)             |                |                |                | 0.165   |
| Non-Hispanic white                | 5,162 (51.8)   | 2,664 (52.2)   | 2,498 (51.3)   |         |
| Non-Hispanic black                | 1,800 (18.1)   | 895 (17.6)     | 905 (18.6)     |         |
| Mexican-American                  | 2,021 (20.3)   | 1,057 (20.7)   | 964 (19.8)     |         |
| Other                             | 989 (9.9)      | 483 (9.5)      | 506 (10.4)     |         |
| PIR, n (%)                        |                |                |                | < 0.001 |
| ≤ 1.30                            | 2,801 (28.1)   | 1,318 (25.8)   | 1,483 (30.4)   |         |
| 1.31~3.50                         | 3,884 (38.9)   | 1,999 (39.2)   | 1,885 (38.7)   |         |
| ≥ 3.51                            | 3,287 (33.0)   | 1,782 (34.9)   | 1,505 (30.9)   |         |
| Education level, n (%)            |                |                |                | < 0.001 |
| Less than HS                      | 2,841 (28.5)   | 1,521 (29.8)   | 1,320 (27.1)   |         |
| HS/GED                            | 2,380 (23.9)   | 1,216 (23.8)   | 1,164 (23.9)   |         |
| Some college                      | 2,751 (27.6)   | 1,285 (25.2)   | 1,466 (30.1)   |         |
| College                           | 2,000 (20.1)   | 1,077 (21.1)   | 923 (18.9)     |         |
|                                   |                |                |                |         |

| Marital status, n (%)          |              |              |              | < 0.001 |
|--------------------------------|--------------|--------------|--------------|---------|
| Married or living with partner | 6,333 (63.5) | 3,539 (69.4) | 2,794 (57.3) |         |
| Other                          | 3,639 (36.5) | 1,560 (30.6) | 2,079 (42.7) |         |
| Smoking, yes, n (%)            | 4,829 (48.5) | 2,903 (57.0) | 1,926 (39.5) | < 0.001 |
| Drinking, yes, n (%)           | 711 (7.4)    | 436 (8.8)    | 275 (6.0)    | < 0.001 |
| Physical inactivity, n (%)     | 3,410 (52.3) | 1,631 (46.8) | 1,779 (58.7) | < 0.001 |
| Unhealthy diet, yes, n (%)     | 5,883 (60.1) | 3,224 (64.4) | 2,659 (55.7) | < 0.001 |
| Unhealthy BMI, yes, n (%)      | 6,774 (71.2) | 3,533 (72.8) | 3,241 (69.5) | < 0.001 |
| Unhealthy lifestyles           |              |              |              | < 0.001 |
| Favorable                      | 2,436 (24.4) | 987 (19.4)   | 1,449 (29.7) |         |
| Intermediate                   | 6,619 (66.4) | 3,557 (69.8) | 3,062 (62.8) |         |
| Unfavorable                    | 917 (9.2)    | 555 (10.9)   | 362 (7.4)    |         |
| PhenoAge, Mean±SD              | 43.6±19.8    | 44.3±20.3    | 42.9±19.2    | 0.005   |

Abbreviations: SD, standard deviation; TDI, Townsend deprivation index; BMI, body mass index; PIR, poverty income ratio; HS/GED, less than
 high school (HS) /general educational development (GED); PhenoAge, Phenotypic Age.

<sup>600</sup> <sup>a</sup>Favorable (unhealthy lifestyle score ranged from 0 to 1), intermediate (unhealthy lifestyle score ranged from 2 to 3), and Unfavorable (unhealthy <sup>601</sup> lifestyle score ranged from 4 to 5) lifestyles.

Table 2. Associations of unhealthy lifestyles with adverse health outcomes and mediation proportion of aging (measured by PhenoAgeAccel)
 in adverse health outcomes attributed to different lifestyles.

| Unhealthy<br>lifestyle | No. of<br>events/No.<br>participants | Model 1 <sup>a</sup> |             | Model 2 <sup>b</sup> |             | Mediation<br>proportion of                | P value |
|------------------------|--------------------------------------|----------------------|-------------|----------------------|-------------|---|---------|
|                        |                                      | HR (95% CI)          | P for trend | HR (95% CI)          | P for trend | PhenoAgeAccel<br>(%)(95% CI) <sup>a</sup> |         |
|                        | UKB                                  |                      |             |                      |             |   |         |
|                        | Incident CVD                         |                      |             |                      |             |   |         |
|                        | 29,726/378,708                       |                      |             |                      |             |   |         |
| Favorable <sup>c</sup> | 4,967/89,538                         | ref                  | < 0.001     | ref                  | < 0.001     | 0.200 (0.182,<br>0.220)                   | < 0.001 |
| Intermediate           | 18,234/226,657                       | 1.33 (1.29, 1.38)    |             | 1.27 (1.23, 1.31)    |             |   |         |
| Unfavorable            | 6,525/62,513                         | 1.59 (1.53, 1.65)    |             | 1.45 (1.39, 1.51)    |             |   |         |
|                        | Incident cancer                      |                      |             |                      |             |   |         |
|                        | 34,413/372,203                       |                      |             |                      |             |   |         |
| Favorable              | 6,695/ 85,776                        | ref                  | <0.001      | ref                  | < 0.001     | 0.178 (0.155,<br>0.200)                   | < 0.001 |

| Intermediate | 20,700/223,155         | 1.15 (1.12, 1.18) |         | 1.12 (1.09, 1.15) |        |                         |        |
|--------------|------------------------|-------------------|---------|-------------------|--------|-------------------------|--------|
| Unfavorable  | 7,018/63,272           | 1.33 (1.29, 1.38) |         | 1.27 (1.22, 1.31) |        |                         |        |
|              | All-cause<br>mortality |                   |         |                   |        |                         |        |
|              | 27,471/405,944         |                   |         |                   |        |                         |        |
| Favorable    | 4,146/93,491           | ref               | < 0.001 | ref               | <0.001 | 0.266 (0.250,<br>0.290) | <0.001 |
| Intermediate | 16,174/243,161         | 1.34 (1.29, 1.39) |         | 1.22 (1.18, 1.26) |        |                         |        |
| Unfavorable  | 7,151/69,292           | 1.84 (1.77, 1.92) |         | 1.55 (1.49, 1.61) |        |                         |        |
|              | NHANES                 |                   |         |                   |        |                         |        |
|              | CVD mortality          |                   |         |                   |        |                         |        |
|              | 258/9,972              |                   |         |                   |        |                         |        |
| Favorable    | 54/2,436               | ref               | 0.175   | ref               | 0.373  | 0.439 (-1.85,<br>4.45)  | 0.100  |
| Intermediate | 181/6,619              | 1.23 (0.90, 1.67) |         | 1.14 (0.83, 1.55) |        |                         |        |
| Unfavorable  | 23/917                 | 1.37 (0.82, 2.28) |         | 1.23 (0.74, 2.05) |        |                         |        |

|              | Cancer mortality       |                   |        |                   |       |                         |        |
|--------------|------------------------|-------------------|--------|-------------------|-------|-------------------------|--------|
|              | 325/9,972              |                   |        |                   |       |                         |        |
| Favorable    | 69/2,436               | ref               | 0.036  | ref               | 0.101 | 0.257 (0.135,<br>1.010) | 0.004  |
| Intermediate | 223/6,619              | 1.22 (0.92, 1.61) |        | 1.15 (0.87, 1.52) |       |                         |        |
| Unfavorable  | 33/917                 | 1.60 (1.04, 2.47) |        | 1.47 (0.95, 2.27) |       |                         |        |
|              | All-cause<br>mortality |                   |        |                   |       |                         |        |
|              | 1,374/9,972            |                   |        |                   |       |                         |        |
| Favorable    | 317/2,436              | ref               | <0.001 | ref               | 0.023 | 0.352 (0.245,<br>0.610) | <0.001 |
| Intermediate | 921/6,619              | 1.11 (0.98, 1.27) |        | 1.04 (0.92, 1.18) |       |                         |        |
| Unfavorable  | 136/917                | 1.48 (1.20, 1.82) |        | 1.34 (1.09, 1.65) |       |                         |        |

605 Abbreviations: PhenoAgeAccel, Phenotypic Age Acceleration; HR, hazard ratios; CI, confidence intervals; CVD, cardiovascular disease;


<sup>606</sup> <sup>a</sup>Model 1 included age; sex; education level; self-reported race/ethnicity; occupational status (UKB only); Townsend deprivation index (TDI)


607 (UKB only); marital status (NHANES only); poverty income ratio (PIR) (NHANES only);

<sup>608</sup> <sup>b</sup>Model 2 additional included PhenoAgeAccel based on model 1.

<sup>609</sup> <sup>c</sup>Favorable (unhealthy lifestyle score ranged from 0 to 1), intermediate (unhealthy lifestyle score ranged from 2 to 3), and Unfavorable

610 (unhealthy lifestyle score ranged from 4 to 5) lifestyles.






#### Fig. 1. Flow chart of two studies (A for UK Biobank and B for NHANES).

614 Abbreviations: UK Biobank: UKB; US National Health and Nutrition Examination Survey: NHANES; CVD, cardiovascular diseases.

# Accelerated aging



617 Fig. 2 The mediating role of aging in the association of unhealthy lifestyles and adverse health outcomes